Autoreactive CD8+ T cell specific for Type 1 Diabetes (T1D)-associated autoantigens (Autoreactive CD8+ T cell)

Autoreactive CD8+ T cells are the primary effector cells responsible for the selective destruction of insulin-producing beta cells in the pancreatic islets, a process that leads to Type 1 Diabetes (T1D) (Coppieters et al., 2012, J. Exp. Med.). These cells recognize specific peptides derived from beta-cell autoantigens—such as insulin, glutamic acid decarboxylase 65 (GAD65), and zinc transporter 8 (ZnT8)—presented by Major Histocompatibility Complex (MHC) class I molecules (Mallone & Roep, 2015, Diabetologia). Upon activation, they infiltrate the pancreas (insulitis) and release cytotoxic molecules like perforin and granzymes to induce beta-cell apoptosis (Knight et al., 2013, Diabetes). Therapeutic strategies, such as the anti-CD3 monoclonal antibody Teplizumab, target these cells to induce immunological exhaustion or promote regulatory T cell (Treg) populations, thereby delaying the loss of C-peptide production (Herold et al., 2019, N. Engl. J. Med.). Other approaches include costimulation blockade with Abatacept or B-cell depletion with Rituximab, which indirectly affects T cell priming and activation (Linsley et al., 2011, J. Clin. Invest.). Monitoring these cells using MHC-peptide tetramers serves as a critical biomarker for identifying individuals at risk and evaluating the efficacy of disease-modifying therapies (Wiedeman et al., 2020, JCI Insight). Understanding the TCR repertoire and antigenic specificity of these cells is essential for developing precision immunotherapies that spare general immune function.

Other names

Diabetogenic CD8+ T cellIslet-reactive CD8+ T cellBeta-cell specific CD8+ T cellInsulin-reactive T lymphocyteAutoreactive cytotoxic T lymphocyte

Modulation of T cell receptor signaling, induction of T cell exhaustion, depletion of activated lymphocyte subsets, and inhibition of costimulatory pathways to prevent autoimmune beta-cell destruction.